Apnimed, Inc.
No enriched coverage for $APMD in the last 7 days.
No SEC Form 4 filings for $APMD in the last 30 days.
See all $APMD insider activity →Apnimed (APMD) announced five abstracts accepted for CHEST 2026, including late-breaking data on Phase 3 trials of AD109 for obstructive sleep apnea (OSA). The company will also host a panel discussion on trial results and their potential impact on OSA management. AD109's NDA is under FDA review with a PDUFA goal date of February 28, 2027.
Apnimed, Inc. (APMD) granted 19 employees stock options for 481,300 shares at $22.54 per share. The options vest over four years. The company is developing AD109, a drug for obstructive sleep apnea, with a PDUFA goal date of February 28, 2027. APMD believes AD109 could expand treatment options for OSA.
Apnimed, Inc. (APMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update • U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi ™, and assigned a PDUFA target action date of February 28, 2027 • If approv
Recent APMD coverage spans ipo, financial news and insider activity.
Positive trial data could lift the stock as investors price in potential FDA approval.
The option grant introduces dilution risk and may modestly pressure the share price.
Positive regulatory milestone and strong earnings boost the company's valuation prospects.
The FDA timeline introduces uncertainty and potential upside if approval is granted, but also risk due to regulator concerns.
Routine insider equity administration plus a fresh option grant, with limited direct implications for near-term fundamentals.
AlphAI scores every news story that mentions APMD with an AI model for sentiment and relevance, and aggregates insider trades from Apnimed, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Apnimed (APMD) announced five abstracts accepted for CHEST 2026, including late-breaking data on Phase 3 trials of AD109 for obstructive sleep apnea (OSA). The company will also host a panel discussion on trial results and their potential impact on OSA management. AD109's NDA is under FDA review with a PDUFA goal date of February 28, 2027.
2 min readApnimed, Inc. (APMD) granted 19 employees stock options for 481,300 shares at $22.54 per share. The options vest over four years. The company is developing AD109, a drug for obstructive sleep apnea, with a PDUFA goal date of February 28, 2027. APMD believes AD109 could expand treatment options for OSA.
1 min readApnimed, Inc. (APMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update • U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi ™, and assigned a PDUFA target action date of February 28, 2027 • If approv
2 min readApnimed's sleep apnea pill AD109 has a February 28, 2027, FDA decision date. The drug showed a 44.1% reduction in breathing interruptions in trials, but the FDA questioned its clinical meaningfulness. Apnimed (APMD) relies on this single product, and its future hinges on FDA approval.
3 min readApnimed, Inc. (APMD) President Dennis Patrick Molnar reported an internal reclassification on Aug. 3, 2026, converting each Class A share into one Common share under SEC Rules 16b-7 and 16b-3. The filing also lists new stock option grants, including 55,596 options at a $16.00 exercise price granted July 30, 2026, vesting monthly over 24 months.
3 min readMorningside Venture Investments Ltd purchased 312,500 shares of Apnimed, Inc. (APMD) at $16.00 ($5.00M total) on 2026-08-03.
2 min readApnimed, Inc. (Nasdaq: APMD) priced and closed an upsized Nasdaq IPO raising $220.8M in gross proceeds. It sold 13.8M shares at $16.00 each, including 1.8M from the underwriters’ overallotment option. Shares began trading July 31, 2026. The company develops AD109 for obstructive sleep apnea, with two Phase 3 trials completed and an NDA PDUFA goal date of Feb. 28, 2027.
2 min readSEKHRI PAUL J purchased 12,500 shares of Apnimed, Inc. (APMD) at $16.00 ($0.20M total) on 2026-08-03.
2 min readApnimed raised $192M in its Nasdaq IPO, pricing 12M shares at $16 and debuting as APMD at $25, up 56% on the day. The company’s lead candidate Oxnimbi (formerly AD109) is under FDA review for obstructive sleep apnea. Apnimed submitted a new drug application in April; the FDA accepted it with a Feb. 28, 2027 decision date.
6 min readApnimed Inc. (Nasdaq: APMD) jumped 56% in its Nasdaq debut after pricing an enlarged $192M IPO. It sold 12M shares at $14-$16, closing at $25. The company reported $84.8M revenue and $67.7M net income for the quarter ended March 31. It is developing Oxnimbi for obstructive sleep apnea, with an FDA marketing request filed in April.
5 min read
